Hyaluronic acid synthetase and application thereof
Through deep-sea-derived hyaluronic acid synthetase, low molecular weight hyaluronic acid is synthesized in vitro using UDP-GlcA and UDP-GlcNAc substrates, solving the problem of difficulty in obtaining low molecular weight hyaluronic acid in the prior art, and achieving high efficiency and environmental protection biosynthesis method.
Patent Information
- Application Number
- CN202411380633.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to efficiently obtain low molecular weight hyaluronic acid, which takes a long time to physical decomposition, and chemical decomposition is not environmentally friendly, and deep-sea-derived hyaluronic acid synthetase has not been reported.
Provided a hyaluronic acid synthetase from the deep sea, with an amino acid sequence of SEQ ID NO.1, a molecular weight of 37.2 kDa, and a transmembrane structure. It can synthesize low molecular weight using UDP-GlcA and UDP-GlcNAc substrates in vitro. Hyaluronic acid, its enzyme activity is verified by enzyme kinetic analysis.
The efficient synthesis of low molecular weight hyaluronic acid in vitro is achieved, providing a basis for the development and utilization of deep-sea gene resources, and has simpler steps, smaller pollution and a more single product than chemical synthesis.
Smart Images

Figure BDA0005069812970000031 
Figure BDA0005069812970000041 
Figure BDA0005069812970000051
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of synthetic biology, and in particular to a hyaluronic acid synthase and an application thereof. Background Art
[0002] Hyaluronan synthase (HAS) is an enzyme that can synthesize hyaluronic acid (HA) in vivo. HASs are glycosyltransferases that have been reported in vertebrates and some microorganisms. In 1993, the first HAS was found in Streptococcus. Since then, HAS have been found in humans and other microorganisms. HAS are divided into two categories according to the number of transmembrane domains, namely protein sequence and domain organization. Class I is an integral membrane protein with a single glycosyltransferase 2 (GT2) domain, 4 to 6 predicted transmembrane regions and 1 to 2 membrane-associated regions, such as Streptococcus HAS, which contains 6 membrane regions, including 4 integral membrane regions and 2 amphipathic membrane domains. In addition, Streptococcus HAS has a cytoplasmic domain and a motif composed of D, D, QXXRW on the cytoplasmic domain, which is essential for the β1→4-linked glycosyltransferase activity. Class II is a peripheral membrane protein with two GT2 domains. To date, there is only one type II HAS, pmHAS from Pasteurella multocida. Each domain in the class II protein is responsible for the catalysis of one glycosidic bond.
[0003] Hyaluronic acid (HA) is a linear glycosaminoglycan with a low molecular weight of 10 to 10 4 kDa, and is commonly found in almost all multicellular organisms and some microorganisms. HA is not only an important structural element in cartilage, synovial fluid, vitreous humor of the eye and skin, but may also play an important role in regulating cell behavior and other biological processes, such as the permeability of vascular walls, the diffusion and manipulation of proteins, water and electrolytes, and promoting wound healing. To date, HA has a wide range of applications in medicine, pharmaceuticals, cosmetics, and diet. HA of different molecular weights (MW) have different property values. High molecular weight HA generally acts as a space filler, osmotic buffer, and viscoelastic structure, medium-sized HA, generally 200-500 kDa in size, can stimulate pro-inflammatory responses in various pathologies, while low molecular weight HA can promote wound healing and anti-adhesion.
[0004] Currently available HAS are divided into two types, namely Class I and Class II, which are derived from humans, mice and specific microorganisms. These two types of HAS have 2 to 7 transmembrane structures and 2 to 6 HA binding sites. , and the molecular weight of HA synthesized by these two types of HAS mostly belongs to high molecular weight or medium molecular weight. In order to obtain HA with a small molecular weight, it is necessary to rely on physical, chemical and biological means for decomposition. Among them, physical decomposition can only obtain limited small molecular weight HA, and it takes a long time; although chemical decomposition takes a short time, it is not environmentally friendly. Therefore, most of the current methods for obtaining HA with a small molecular weight are biodegradation. The deep sea contains rich genetic resources, and there is no report on HAS derived from the deep sea, and there is no report on whether HAS derived from the deep sea can synthesize HA. Therefore, the present invention provides a hyaluronic acid synthase derived from the deep sea for synthesizing low molecular weight hyaluronic acid. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the present invention proposes a hyaluronic acid synthase and its application to solve the problems raised by the above-mentioned background technology.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] A hyaluronan synthase, the amino acid sequence of the hyaluronan synthase is shown as SEQ ID NO.1.
[0008] Preferably, the hyaluronan synthase has no transmembrane structure and has only one hyaluronan binding protein with a molecular weight of 37.2 kDa.
[0009] Preferably, the nucleotide sequence of the primer used to amplify hyaluronan synthase is:
[0010] F1: 5'-ATGAAATATACTATTCTTATTCC-3' (SEQ ID NO. 2);
[0011] R1: 5'-TATATAGAATATATGGATATTAA-3' (SEQ ID NO. 3).
[0012] Preferably, the hyaluronan synthase is used in synthesizing hyaluronic acid.
[0013] Preferably, a method for synthesizing hyaluronic acid comprises the following steps:
[0014] (1) obtaining the above-mentioned hyaluronan synthase;
[0015] (2) Utilizing the hyaluronan synthase in step (1) to catalyze the synthesis of hyaluronic acid in an enzyme activity reaction system.
[0016] Preferably, in step (1), hyaluronan synthase is obtained by molecular cloning and expression.
[0017] Preferably, the enzyme activity reaction system in step (2) contains 30 μM of the hyaluronic acid synthase according to claim 1, 50 mM PBS buffer, 15 mM magnesium chloride solution, 2.5 mM dithiothreitol solution, 1 mM UDP-GlcA and 1 mM UDP-GlcNAc.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] (1) The HAS obtained by the present invention helps to understand the sequence characteristics and functional features of HAS from the deep sea, and helps to develop and utilize deep-sea genetic resources. Through experiments and data analysis, we know that the HAS of the present invention is different from the two types of HAS reported. It has a smaller molecular weight (molecular weight of 37.2kDa), only one HA binding site, and no transmembrane structure, while the other two types of HAS have relatively large molecular weights (molecular weights of 47.33-112kDa), 2-6 HA binding sites, and 2-7 transmembrane structures.
[0020] (2) By performing enzyme kinetic analysis on the HAS obtained by the present invention, it was found that the HAS can synthesize two small molecular weight HAs using two substrates (UDP-GlcA and UDP-GlcNAc) in vitro, which provides raw materials and theoretical basis for the subsequent utilization of small molecular weight HA.
[0021] (3) The hyaluronan synthase sequence obtained by the present invention is a valuable deep-sea biological gene resource. Its own sequence characteristics and ability to synthesize low-molecular-weight hyaluronic acid provide a basis and theoretical foundation for the further development and utilization of deep-sea gene resources.
[0022] (4) Compared with the prior art, the present invention utilizes an enzyme-catalyzed biosynthesis method to obtain hyaluronic acid, which has the advantages of simpler steps, less pollution, and a more uniform product compared with chemical synthesis. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the electrophoresis band diagram of HAS gene;
[0024] Figure 2 It is a comparison diagram of the amino acid sequences of HAS of the present invention and HAS from other biological sources;
[0025] Figure 3 The phylogenetic tree and classification diagram of the HAS of the present invention and HAS from other species;
[0026] Figure 4Schematic diagram of the Michaelis constant determination results of the HAS of the present invention for two substrates UDP-GlcNAc and UDP-GlcA. DETAILED DESCRIPTION
[0027] The technical solution of the present invention is further described in detail below in conjunction with specific implementation methods.
[0028] Example 1 HAS gene acquisition
[0029] The genome of the intestinal symbiotic microorganism "Candidatus Mycoplasmaliparidae" from deep-sea lionfish has been sequenced, assembled and annotated in the early stage, and the HAS gene has been discovered. Total RNA was extracted from the intestine of deep-sea lionfish using a total RNA extraction kit, and a single-stranded cDNA was generated using a reverse transcription kit with a gDNA wiper. This was used as a template for polymerase chain reaction (PCR) amplification of the full-length fragment of the HAS gene. The specific primer information is shown in Table 1, and the electrophoresis band diagram is shown in Figure 1 :
[0030] Table 1 Primer sequences
[0031]
[0032] The PCR reaction system was: 1 μL cDNA, 1 μL each of 10 μmol / L upstream and downstream primers, 12.5 μL 2× Phanta Max MasterMix, and ddH2O to make up to 25 μL.
[0033] PCR amplification reaction program: pre-denaturation at 98°C for 10s; denaturation at 98°C for 10s, annealing at 50°C for 30s, extension at 72°C for 1min, 30 cycles; extension at 72°C for 10min; storage at 4°C.
[0034] Example 2 HAS gene cloning
[0035] The PCR amplification product of the HAS gene was recovered by gel extraction with MinElute Gel Extraction Kit (Qiagen, Germany) using homologous recombinase and ligated with the pMD18-T vector (Takara, Japan) to obtain a recombinant plasmid. The recombinant plasmid was transformed into competent cells Escherichia coli DH 5α (Takara, Japan), and then the bacterial solution was spread on LB plates containing ampicillin (50 mg / L) and cultured at 37°C for 12 h. The successfully transformed positive clones were amplified and cultured in LB liquid culture medium. The plasmids were extracted from the competent cells using EZNAR Plasmid DNA Mini Kit I (Omega, USA), and the inserted fragments in the plasmid were sequenced to obtain the full-length sequence of the HAS gene.
[0036] The amino acid sequence obtained by HAS sequencing is shown in SEQ ID NO.1, and the gene sequence contains 310 amino acids.
[0037] SEQ ID NO.1:
[0038] MKYTILIP C YNAEKYISR C LNSIVNQDYQDFEIIVLNDGSTDNSLAILNSYQEKDQRIKIISRENKGLSVTRNDLIKKVHTDYFYFI D ADDWIELNTFSTFDMKLKEVNFVVDMIINSTFINKKNKSKTFYITNKIDENTTNESYLINNTPYAWNILIRKEYLLENKFSF C Q E YNYFEDAGSSVSFWIYKTKNIIFLNHPNYHYFINK Q SLS R ANISFEKISAGISQLENFYSLLKSDNVLIKDNKPINDQLAFYHSVIFSHIQFETKVNKSE KNILKTRLR SLEKDNVNLKFPRRYWKFWYFVLYRIYGY.
[0039] The amino acid sequence SEQ ID NO.1 of the HAS of the present invention was compared with the amino acid sequences of HAS from other biological sources, and it was found that the amino acid sequence of the HAS of the present invention is different from the existing amino acid sequences, see Figure 2As shown in the figure, the phylogenetic tree and classification of the HAS of the present invention and HAS from other species are compared. According to the phylogenetic relationship analysis, the HAS of the present invention is grouped together with the three HAS from Mycoplasmatota, and does not belong to the two reported Class I / II HAS, see Figure 3 shown.
[0040] The transmembrane structure, HA binding domain, molecular weight and pI prediction of HAS (Organisms: "Candidatus Mycoplasma liparidae") of the present invention were compared with those of HAS from different sources. The results are shown in Table 2:
[0041] Table 2 Prediction of transmembrane structure, HA binding domain, molecular weight and pI of HAS from different sources
[0042]
[0043] Tests have shown that the HAS of the present invention has a unique structure. Hyaluronic acid does not have a transmembrane structure and has only one hyaluronic acid binding protein with a molecular weight of 37.2 kDa. The predicted conserved sites are: 88D, 208Q, DGSTD (38-42aa), DXDD (88-91aa); the HA binding point is 273-281aa (KNILKTRLR), which is different from the existing HAS discovered.
[0044] Example 3 HAS gene expression and purification
[0045] The target gene was amplified by PCR using the designed primers, and the amplified product was purified by gel cutting. The purified PCR product and expression vector were double-digested with appropriate restriction endonucleases, and the purified digested products were ligated with T4 ligase (Takara, Japan). The recombinant plasmids that were successfully connected after sequencing were transformed into competent cells E. coli BL21 Codon Plus (Novagen, USA), and the positive clones after transformation were picked and amplified in LB liquid medium containing ampicillin (50 mg / L). When the bacterial solution was cultured to OD 600When the p-value was 0.6, IPTG (isopropyl-β-D-thiogalactopyranoside) was added at a final concentration of 0.2-0.5 mM to induce the expression of the target gene. After culturing at 25°C for 16 h, the cells were collected by centrifugation, resuspended in lysis buffer (Na2HPO4 80 mM, NaCl 1.36 M, KH2PO4 20 mM, KCl 26 mM, 1% TRITONX-100, pH 8.0), and disrupted using an ultrasonic disruptor (Fisher, USA). The recombinant protein released after disruption was purified using a Histag protein purification kit, and the purified product was tested by 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis, and the concentration of the purified protein was determined using a DC Protein Assay Kit (Bio-Rad, USA).
[0046] Example 4 In vitro enzyme activity detection
[0047] The HAS enzyme activity experimental system is: 50mM PBS, 15mM MgCl, 2.5mM DTT, 1mM UDP-GlcA, 1mMUDP-GlcNAc and 30μM purified HAS, with a total volume of 50μl. The reaction system is reacted at 37℃ for 1h. After boiling, the HA product in the reaction system is detected using the HA detection kit. The kit uses HA binding protein and horseradish peroxide as primary and secondary antibodies. After the reaction, TMB is used for color termination. The OD value is measured using an enzyme reader. 450 The absorbance of the product was detected under the same conditions. Three parallel samples were set for all the reaction systems.
[0048] The results of in vitro enzyme activity detection are shown in Table 3:
[0049] Table 3 In vitro enzyme activity detection-Michaelis constant
[0050]
[0051] The results of the Michaelis constant determination of HAS for two substrates UDP-GlcNAc and UDP-GlcA are as follows Figure 4 As shown, the K of the snHAS of the present invention to the substrate UDP-GlcNAc m The value was 0.26±0.05mM, which was significantly lower than that of HAS from other sources (the K value of spHAS from Streptococcus pygenes was m The K value of seHAS from Streptococcus equisimilis was 1.09 ± 0.12 mM. m The value is 0.95±0.17mM, and the K of HAS1 from Mouse mThe Km value of the snHAS of the present invention for the substrate UDP-GlcA is 0.04±0.01 mM, which is similar to that of HAS from other sources.
[0052] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A hyaluronic acid synthase, characterized in that The amino acid sequence of the hyaluronan synthase is shown in SEQ ID NO.
1.
2. A hyaluronic acid synthase according to claim 1, characterized in that The hyaluronan synthase does not have a transmembrane structure and has only one hyaluronan binding protein with a molecular weight of 37.2 kDa.
3. Primers for amplifying the hyaluronan synthase according to claim 1.
4. The primer according to claim 3, characterized in that The nucleotide sequence of the primer is: F1: 5'-ATGAAATATACTATTCTTATTCC-3'; R1: 5'-TATATAGAATATATGGATATTAA-3'.
5. Use of the hyaluronan synthase according to claim 1 in synthesizing hyaluronic acid.
6. A method for synthesizing hyaluronic acid, characterized in that: The method comprises the following steps: (1) obtaining the hyaluronan synthase according to claim 1; (2) Utilizing the hyaluronan synthase in step (1) to catalyze the synthesis of hyaluronic acid in an enzyme activity reaction system.
7. The method for synthesizing hyaluronic acid according to claim 6, characterized in that: In step (1), hyaluronan synthase is obtained by molecular cloning and expression.
8. The method for synthesizing hyaluronic acid according to claim 6, characterized in that: The enzyme activity reaction system in step (2) contains 30 μM of the hyaluronic acid synthase according to claim 1, 50 mM PBS buffer, 15 mM magnesium chloride solution, 2.5 mM dithiothreitol solution, 1 mM UDP-GlcA and 1 mM UDP-GlcNAc.
Citation Information
Patent Citations
Nucleic acid encoding hyaluronan synthase and methods of use
CN101275143A
Preparation method of hyaluronic acid with different molecular weights
CN117327754A
Hyaluronan synthase gene and uses thereof
CN1283224A
Polypeptide having hyaluronic acid synthase activity, method for producing the same and method for producing hyaluronic acid utilizing the same
JP2004000026A
Hyaluronic acid synthase and its gene
JP2006204260A
